NCT01487551View on ClinicalTrials.gov

An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)

PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Systemic Sclerosis

Interventions

DRUG

paquinimod

Hard gelatine capsules 3.0 mg/day for 8 weeks

Trial Locations (6)

Unknown

Berlin

Cologne

Erlangen

Gothenburg

Lund

Zurich

Sponsors

Lead Sponsor

Active Biotech AB

All Listed Sponsors

lead

Active Biotech AB

INDUSTRY

NCT01487551 - An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) | Biotech Hunter | Biotech Hunter